Dr. Morrison received his B.S. in biology from Georgetown University, his M.D. from the University of Connecticut Medical School, completed residency training in Internal Medicine at the Massachusetts General Hospital, and completed a fellowship in Medical Oncology at Dana-Farber Cancer Institute. He did postdocs with Philip Leder at Harvard Medical School, and Lee Nadler at the Dana-Farber. He joined Merck & Co., Inc. in 1995, was appointed Head of Clinical Development at Pfizer in 2007, and became Head of Global Medicines Development and Chief Medical Officer at AstraZeneca in 2012. He is currently President, Head of R+D and a board member at Syndax Pharmaceuticals (NASDAQ: SNDX) and an Executive Partner at MPM Capital.
Dr. Morrison has overseen the development of numerous biopharmaceutical products in multiple therapeutic areas, from first-in-human trials through to global regulatory approvals. He is currently a board member of Arvinas (NASDAQ: ARVN), Werewolf (NASDAQ: HOWL) and Repare Therapeutics (NASDAQ: RPTX) and is an advisor to several other private biotechnology companies.